For many antibody therapeutics targeting solid tumors, efficacy is not determined solely by binding affinity or target but by the ability of the molecule to reach its site of action within the tumor tissue.
Penetration into dense tumor tissue remains a major barrier. Tumor microenvironment characteristics such as extracellular matrix density, cell population diversity, elevated interstitial pressure, and antigen-mediated binding-site barriers can all restrict antibody diffusion and lead to heterogeneous intratumoral distribution. As a result, parts of the tumor may receive insufficient antibody exposure, limiting target engagement and therapeutic benefit, and in some cases contributing to treatment resistance.
Most antibody therapeutics act at the cellular surface within the tumor interstitium. Reaching this compartment requires crossing multiple physical and biological barriers to achieve homogeneous distribution. Conventional 2D assays fail to capture the architectural complexity of tumors, including cell-cell interaction, oxygen and nutrient gradients that may influence target expression. Meanwhile, in vivo studies are costly, time-consuming, and not suitable for early-stage screening of multiple biologic candidates.
Our established 3D InSight™ Tumor Penetration Screening platform enables scalable, image-based evaluation of biologics antibody penetration and target localization in human 3D tumor models at single-cell resolution.
This high-content image screening approach supports early biologics (e.g. IgG, bispecific antibodies, ADCs) selection by providing quantitative insight into how therapeutic antibodies penetrate within solid tumor tissue models before further pre-clinical efficacy studies.
Explore our standardized study design used to evaluate antibody penetration and distribution in 3D tumor microtissues.
Using reproducible human 3D solid tumor microtissues derived from multiple tissue types, tailored to your therapeutic target, our platform enables direct comparison of different biologic formats.
Human 3D tumor models capturing key microenvironment features, including cellular architecture and extracellular matrix (ECM), for predictive, reliable antibody penetration and distribution analysis.
Evaluate a wide range of biologics from monoclonal antibodies to next-generation antibody-based therapeutics, within the same standardized platform.
Efficiently compare multiple antibody candidates to support early, data-driven selection and optimization decisions.
Generate reliable, reproducible data within streamlined workflows designed to accelerate discovery timelines
Access highly standardized human 3D tumor microtissues generated from a broad panel of 30+ cancer cell lines across 11 tissue types, including breast, pancreatic, and colorectal cancer. These models can be generated as tumo-only culture or co-culture with cancer-associated fibroblast to mimic the tumor complexity. This variety of models allows you to evaluate antibodies in disease-relevant tumor setting and screen candidates in the specific cancer type of interest.
Produced under stringent QC, these physiologically relevant tumor models capture key features of the tumor microenvironment and are designed for reliable antibody penetration screening, optimization, and comparative studies across programs.
Figure: β-integrin penetration within different 3D InSight™ tumor models. 3D Breast, Lung or Pancreatic TuMT spheroids were treated with β-integrin for 24h. Fixed spheroids are immune-stained with a secondary antibody conjugated with an Alexa488 and the DNA intercalant DAPI. Images represent the middle section of a representative spheroid. Scale:100 µm
Assess tumor penetration and intratumoral distribution across a wide range of biologic formats, including: full-length IgGs, antibody fragments, DARPin® molecules, Antibody-drug conjugate (ADC), and recombinant antibodies.
Using standardized human 3D tumor microtissues, different biologic formats can be directly compared within the same experimental model.
This enables a clear assessment of the spatial distribution and supports the selection of the most effective antibody format and candidates for further development.
Figure: Comparison of penetration depth of Cetuximab and Cetuximab-MMAE in 3D InSight™ A549 tumor model. 3D A549-TuMT spheroids were treated with cetuximab or cetuximab-MMAE at a concentration of 0.8 μg/ml for 0.5h, 1h, 3h, 6h, or 24h prior to fixation. Fixed spheroids were stained with fluorescent-conjugated antibodies (Alexa488, green) and the DNA intercalant DAPI (blue) and then processed for confocal image analysing, Middle section of a spheroid is shown. Bar graphs represent tumor penetration depth. Scale:100 µm
Our established high-throughput high-content imaging (HCI) workflow delivers quantitative, spatially resolved data at the single-cell level, including:
Figure: Overview of the antibody penetration pipeline. (1) The spheroid is detected based on DAPI nuclear staining, and the middle section (largest area) z-section is selected. (2) Antibody penetration depth is quantified by averaging depth in all directions. (3) Penetration analysis is presented in a graphical format. Scale:100 µm
Getting started with our 3D InSight™ Tumor Penetration Screening service is fast and straightforward. Ship your antibodies to our team, and we will evaluate their target expression (optional), tumor penetration and cell viability in our 3D tumor models.
You’ll receive high-quality, actionable results in a comprehensive report within 3 weeks, designed to support confident decision-making and advance the most promising biologic candidates to the next stage of development
Week 1: Once received, we design a study setup aligned with your target and cancer model.
Week 1: We prepare standardized human 3D tumor microtissues tailored to your cancer type.
Week 2: Optional target expression assessment helps ensure biologically relevant testing conditions.
Week 2: Antibodies are tested at defined time points to assess penetration, distribution, and cellular impact using multiplex imaging.
Week 3: Receive a comprehensive report with spatial metrics and insights to support candidate prioritization and development decisions.
3D InSight™ Tumor Penetration Screening evaluates how effectively antibody therapeutics distribute within tumor microtissues using high-content imaging. It measures how well biologics such as monoclonal antibodies, bispecific antibodies, or antibody–drug conjugates penetrate and reach their cellular targets within the tumor microtissue.
Understanding antibody penetration in 3D solid tumor models early helps identify candidates that achieve sufficient intratumoral exposure and target engagement before pre-clinical efficacy studies.
Early tumor penetration screening helps identify biologic candidates with optimal antibody penetration properties before expensive in vivo studies. By comparing multiple antibody formats in physiologically relevant tumour models, researchers can prioritise antibody candidates with better penetration, more uniform intratumoral distribution, and higher potential for therapeutic efficacy.
Antibody penetration into solid tumors is limited by barriers within the tumor microenvironment, including dense extracellular matrix, diverse cell populations, elevated interstitial pressure, and antigen-mediated binding-site barriers. These factors restrict antibody diffusion and lead to heterogeneous intratumoral distribution, meaning some tumor regions receive insufficient exposure. Because most antibodies act at the cellular surface within the tumor interstitium, they must overcome multiple physical and biological barriers to achieve uniform distribution.
3D in vitro tumor models better replicate the architecture and microenvironment of solid tumors compared to traditional 2D cell cultures. They capture important features such as cell–cell interactions, extracellular matrix structure, and oxygen and nutrient gradients that influence antibody transport and target expression. And to study them in mouse models is costly, time-consuming, and not suitable for early-stage screening of multiple biologic candidates.
Thus, physiologically relevant, scalable 3D in vitro solid tumor models are more predictive for evaluating antibody penetration during high-throughput screening.
With 3D InSight™ Tumor Penetration Screening, one can evaluate a wide range of antibody-based therapeutics. These include full-length IgG antibodies, bispecific antibodies, antibody fragments, antibody–drug conjugates (ADCs), DARPin® molecules, and other engineered biologics.
Testing multiple formats within the same experimental platform allows direct comparison of penetration and distribution properties.
High-content imaging–based tumor penetration screening provides spatial and quantitative insights into antibody penetration and distribution within 3D tumor microtissues. This includes penetration depth, radial distribution within tumor microtissues, temporal distribution over time, and heterogeneity of target expression. These measurements help researchers understand how antibody therapeutics distribute at single-cell resolution.
Fill in form below to contact our 3D in vitro experts
Get the latest news on 3D in vitro research
Fill in the form below to view this resource
